Les informations présentées dans l’Outil de recherche personnalisé d’essais cliniques de Myélome Canada sont issues de la base de données des essais cliniques internationaux du site
ClinicalTrials.gov,
répertoriées par la U.S. National Library of Medicine. Bien que le menu soit en français, les détails des études ne sont offerts qu’en anglais.
Liquid Biopsy Evaluation and Repository Development at Princess Margaret (LIBERATE)
*Les informations de l'essai contenues sur cette page ont été récupérées du site ClinicalTrials.gov. Cliquez ici pour voir cet essai sur ClinicalTrials.gov.
- Titre complet:
- Liquid Biopsy Evaluation and Repository Development at Princess Margaret
- Stade ou Condition:
- Cancer Breast Cancer Lung Cancer Colon Cancer Ovarian Cancer Melanoma Lymphoma Leukemia Mutation Lynch Syndrome Cowden Syndrome BRCA1 Mutation BRCA2 Mutation Uterine Cancer Myeloma Kidney Cancer Head and Neck Cancer Meningioma
- Phase d'étude:
- Résumé:
- The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.
- Description détaillée:
- Non disponible
- Traitements:
- Groupes d'étude:
- : LIBERATE
Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
- Type d'étude:
- Observational
- Protocole de l'étude:
- Observational Model: Cohort
- Time Perspective: Prospective
- Statut du recrutement:
- En cours
- Critères d'admissibilités:
-
Inclusion Criteria:
-
1. Patients with either histological confirmation of a solid tumor or hematological
malignancy, OR patients identified as high-risk for cancer (based on identified
aberration in cancer predisposition gene or on hormonal and/or family history without
known aberration).
2. Patient must be ≥ 18 years old.
3. All patients must have signed and dated an informed consent form for this LIBERATE
study.
4. If patients are being co-consented for a separate primary research study listed in
Appendix I, they must fulfill the eligibility criteria for that separate primary
research study. If there is a discrepancy in the eligibility criteria between
protocols, the separate primary research study's criteria take precedence.
-
None
- Lieux / Centres:
-
Princess Margaret Cancer Centre, Toronto, Ontario – En cours
- Contacts:
- Name: Celeste Yu, MSc
Phone: 416-946-4501
Extension: 5281
Email: [email protected]
- Publications:
- ???
- Date d’affichage:
- 2018-10-11
- Date de début:
- August 3, 2017
- Dernière mise à jour:
- 2023-12-05
- Nombre d'inscriptions anticipées:
- 2500
- Date de fin prévue:
- 2024-07-06
- Date de fin prévue de l'étude primaire:
- 2024-07-06
- Condition:
- Cancer
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Ovarian Cancer
- Melanoma
- Lymphoma
- Leukemia
- Mutation
- Lynch Syndrome
- Cowden Syndrome
- BRCA1 Mutation
- BRCA2 Mutation
- Uterine Cancer
- Myeloma
- Kidney Cancer
- Head and Neck Cancer
- Meningioma
- Genre:
- All
- Âge:
- 18 Years-N/A
- Accepte des bénévoles en santé:
- Accepts Healthy Volunteers
- Pays participants:
- Canada
- Numéro d’identification:
- NCT03702309
- Autres numéros d'identification de l'étude:
- LIBERATE
- Comité de suivi des données:
- No
- Produit réglementé par la FDA (É-U):
- No
- IPD Sharing Statement :
- ???
- Responsables de l’étude:
-
Sponsor
- Commanditaires de l’étude:
- lead_sponsor
University Health Network, Toronto
Other
- Collaborators:
- ???
- Chercheurs:
- Lillian Siu, MD Princess Margaret Cancer Centre
- Protocol Registration and Results System:
- ???
- Date de vérification:
- 2023-12-01